IP Library Granted Patent US 10,196,449
Granted Patent B2
US 10,196,449 · App. 14/763,264 · Granted Feb 5, 2019

Method and kit for detecting 1,25-dihydroxyvitamin D and related antibodies

Inventors: Joshua Soldo (Prior Lake, MN); Gregory Olson (Lakeland, MN); Michael Lutterman (New Brighton, MN); John Wall (Woodbury, MN); Michael New (Bloomington, MN); Hector Floyd Deluca (Deerfield, WI); Fabrizio Bonelli (Casale Monferrato, IT)
Assignee: DiaSorin S.p.A.
C07K16/2869C07K16/26G01N33/82C07K2317/32
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,196,449
App. No.
14/763,264
Granted
Feb 5, 2019
Kind
B2
Abstract

There is disclosed an assay method for selectively detecting 1,25-dihydroxy-vitamin D in a biological fluid sample. According to the method of the invention, the pH of the test sample is adjusted to 6-9 and a receptor protein comprising the Ligand Binding Domain of Vitamin D Receptor (VDR-LBD) is added to the test sample, thereby obtaining the formation of a VDR-LBD/1,25-dihydroxyvitamin D complex in which the VDR-LBD portion is conformationally changed with respect to unbound VDR-LBD. The VDR-LBD/1,25-dihydroxyvitamin D complex is then detected by means of a capture moiety which is capable of specifically binding to VDR-LBD bound to 1,25-dihydroxyvitamin D. Also disclosed are an assay kit and an antibody for carrying out the method of the invention. The assay of the invention is preferably a sandwich immunoassay.

Claims (4)

1. A monoclonal antibody which binds to the complex formed between the Ligand Binding Domain of Vitamin D Receptor (VDR-LBD) and 1,25-dihydroxyvitamin D, wherein the amino acid sequences of the CDRs of the heavy chain variable domain of the monoclonal antibody are SEQ ID NOs: 1, 2 and 3, and the amino acid sequences of the CDRs of the light chain variable domain of the monoclonal antibody are SEQ ID NOs: 4, 5 and 6.

2. The monoclonal antibody according to claim 1 , wherein the heavy chain variable domain comprises the amino acid sequence SEQ ID NO:7 or is encoded by a nucleic acid sequence comprising SEQ ID NO: 8.

3. The monoclonal antibody according to claim 1 , wherein the light chain variable domain comprises the amino acid sequence SEQ ID NO:9 or is encoded by a nucleic acid sequence comprising SEQ ID NO:10.

4. The monoclonal antibody according to claim 2 , wherein the light chain variable domain comprises the amino acid sequence SEQ ID NO:9 or is encoded by a nucleic acid sequence comprising SEQ ID NO:10.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 10, 2022
From: DIASORIN S.P.A.
To: DIASORIN ITALIA S.P.A.
Reel/Frame 061363/0897 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 27, 2015
From: SOLDO, JOSHUA; OLSON, GREGORY; LUTTERMAN, MICHAEL; WALL, JOHN; NEW, MICHAEL; DELUCA, HECTOR FLOYD; BONELLI, FABRIZIO
To: DIASORIN S.P.A.
Reel/Frame 036183/0219 →
Priority Claims (1)
EP 13152851 · Jan 28, 2013 · regional
Continuity (1)
Related Publication 20150361178A1 · Dec 17, 2015